Quantum Genomics SA (ALQGC) - Cash Flow Conversion Efficiency

Latest as of June 2023: -4.706x

Based on the latest financial reports, Quantum Genomics SA (ALQGC) has a cash flow conversion efficiency ratio of -4.706x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-7.64 Million ≈ $-8.93 Million USD) by net assets (€1.62 Million ≈ $1.90 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Quantum Genomics SA - Cash Flow Conversion Efficiency Trend (2012–2022)

This chart illustrates how Quantum Genomics SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read ALQGC total debt and obligations for a breakdown of total debt and financial obligations.

Quantum Genomics SA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Quantum Genomics SA ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Tarapur Transformers Limited
NSE:TARAPUR
1.083x
DOREL INDS INC. A
F:DO4C
N/A
Throgmorton Trust Plc
LSE:THRG
0.018x
Alzinova AB
ST:ALZ
-0.039x
E-Pango SA
PA:ALAGO
0.368x
SIV Capital Ltd
AU:SIV
0.020x
Astrotech Corp
NASDAQ:ASTC
-0.228x
Co-Diagnostics, Inc. Common Stock
NASDAQ:CODX
-0.301x

Annual Cash Flow Conversion Efficiency for Quantum Genomics SA (2012–2022)

The table below shows the annual cash flow conversion efficiency of Quantum Genomics SA from 2012 to 2022. For the full company profile with market capitalisation and key ratios, see how much is Quantum Genomics SA worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2022-12-31 €3.61 Million
≈ $4.22 Million
€-20.21 Million
≈ $-23.63 Million
-5.603x -218.28%
2021-12-31 €9.67 Million
≈ $11.30 Million
€-17.02 Million
≈ $-19.89 Million
-1.760x -261.87%
2020-12-31 €24.65 Million
≈ $28.82 Million
€-11.99 Million
≈ $-14.02 Million
-0.486x +56.12%
2019-12-31 €9.41 Million
≈ $11.00 Million
€-10.43 Million
≈ $-12.19 Million
-1.109x -20.70%
2018-12-31 €11.87 Million
≈ $13.87 Million
€-10.90 Million
≈ $-12.74 Million
-0.919x -2.15%
2017-12-31 €8.87 Million
≈ $10.37 Million
€-7.98 Million
≈ $-9.33 Million
-0.899x -91.70%
2016-12-31 €11.79 Million
≈ $13.79 Million
€-5.53 Million
≈ $-6.47 Million
-0.469x -19.75%
2015-12-31 €8.02 Million
≈ $9.38 Million
€-3.14 Million
≈ $-3.67 Million
-0.392x -101.82%
2014-12-31 €-129.79K
≈ $-151.74K
€-2.79 Million
≈ $-3.26 Million
21.503x +3447.81%
2013-12-31 €-1.63 Million
≈ $-1.90 Million
€-987.00K
≈ $-1.15 Million
0.606x -9.37%
2012-12-31 €-918.08K
≈ $-1.07 Million
€-614.00K
≈ $-717.83K
0.669x --

About Quantum Genomics SA

PA:ALQGC France Biotechnology
Market Cap
$5.87 Million
€5.02 Million EUR
Market Cap Rank
#28337 Global
#516 in France
Share Price
€0.07
Change (1 day)
+0.00%
52-Week Range
€0.07 - €0.07
All Time High
€9.73
About

Quantum Genomics Société Anonyme is in the process of liquidation of its remaining assets. Previously, the company was engaged in the development of drugs to treat cardiovascular diseases. Quantum Genomics Société Anonyme was incorporated in 2005 and is headquartered in Paris, France.